共 186 条
[1]
Torre LA(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108
[2]
Bray F(2006)Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 4991-4997
[3]
Siegel RL(2008)Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36-46
[4]
Ferlay J(2009)Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 666-673
[5]
Lortet-Tieulent J(1997)Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261-267
[6]
Jemal A(2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697
[7]
Van Cutsem E(2014)Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) Br J Cancer 110 1163-1168
[8]
Moiseyenko VM(2014)Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study J Clin Oncol 32 2039-2049
[9]
Tjulandin S(2017)Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study Lancet Oncol 18 640-653
[10]
Majlis A(2003)Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study J Clin Oncol 21 46-53